INN GEAR LIMITED

Financial Health Assessment: INN GEAR LIMITED

1. Financial Health Score: B+

Explanation: INN GEAR LIMITED exhibits a strong and accelerating operational "heartbeat," evidenced by impressive revenue growth and robust cash generation. However, the company's structural "bone density" (net assets/equity) is relatively thin compared to its total size, a condition resulting from years of aggressive dividend extractions. While the business is highly active and generating healthy cash flows, its low equity reserves mean it has less of a buffer against sudden economic trauma or market shocks.

2. Key Vital Signs

• Revenue (Heartbeat): £14.41M (2024), up 20.5% from £11.96M (2023). The company's pulse is strong. A 20.5% increase in a mature manufacturing and fitting business indicates robust market demand and successful contract acquisition.
• Cash Position (Blood Pressure): £859.6k (2024), up from £462.5k (2023). The company's cash flow is pumping effectively, nearly doubling its cash on hand despite significant dividend payouts. This is a very healthy vital sign.
• Net Assets (Immune Reserves): £534.9k (2024), up slightly from £478.6k (2023). While positive, this figure is notably low for a company turning over £14.4M. Historically, net assets were much higher (e.g., £1.38M in 2018, £1.52M in 2016). The "reserves" have been depleted over time.
• Gross Profit Margin (Nutritional Intake): 21.4% (2024), up from 19.9% (2023). The business is absorbing its cost of materials and labor well, improving its efficiency despite external inflationary pressures.

3. Diagnosis

Symptoms Analysis: The financial data reveals a business that is operationally fit but financially leveraged. The primary "symptom" is the disparity between the company's massive turnover and its tiny equity base. The balance sheet shows Total Assets of £3.16M against Total Liabilities of £2.58M.

The underlying cause of this thin equity base is clear: the directors have consistently extracted profits as dividends rather than retaining them to build internal reserves. In 2024 alone, the company declared dividends of £682,760. When you factor in that net assets only grew by £56,316 year-on-year, it becomes apparent that almost all of the £739k operating profit (calculated as Net Asset Growth + Dividends) was siphoned out of the business.

Prognosis: The short-term prognosis is highly favorable. The company has demonstrated an ability to grow sales, improve margins, and generate cash even while fighting off the "inflammation" of rising labor and material costs. However, the long-term prognosis carries a cautionary note. With net assets of just £534.9k supporting a £14.4M operation, the company is highly sensitive to supply chain disruptions, contract losses, or sudden cost spikes. A minor drop in the gross margin or a delay in debtor payments could quickly lead to a cash flow "heart attack" because there are minimal internal reserves to fall back on.

4. Recommendations

To improve overall financial wellness and build resilience against future market "illnesses," the following actions are recommended:

• Retain Earnings to Build Reserves (Build Bone Density): Consider moderating dividend payouts for the next 12-24 months. Retaining a larger portion of the £700k+ annual profits will bolster net assets, creating a stronger safety net and reducing reliance on external liabilities.
• Reinvest in Capital Equipment (Physical Therapy): Capital expenditure dropped dramatically from £138k in 2023 to just £36k in 2024. As a furniture manufacturer and fitter, the company's operational health relies on up-to-date machinery and transport. Deferring capital expenditure for too long can lead to operational inefficiencies and breakdowns.
• Manage Cost Inflation (Preventative Care): The directors noted rising labor and material costs. While the gross margin improved this year, the company must continue to proactively manage these through fixed-price supplier contracts, operational efficiency, and strategic pricing to ensure these cost pressures do not erode profitability in 2025.